Advanced search

Patient dosimetry after I-131-MIBG therapy for neuroblastoma and carcinoid tumours.

MA MONSIEURS, Hubert Thierens (UGent), Anne Vral (UGent), B BRANS, Leo De Ridder (UGent) and Rudi Dierckx (UGent)
Author
Organization

Citation

Please use this url to cite or link to this publication:

Chicago
MONSIEURS, MA, Hubert Thierens, Anne Vral, B BRANS, Leo De Ridder, and Rudi Dierckx. 2001. “Patient Dosimetry After I-131-MIBG Therapy for Neuroblastoma and Carcinoid Tumours.” Nuclear Medicine Communications 22 (4): 367–374.
APA
MONSIEURS, MA, Thierens, H., Vral, A., BRANS, B., De Ridder, L., & Dierckx, R. (2001). Patient dosimetry after I-131-MIBG therapy for neuroblastoma and carcinoid tumours. NUCLEAR MEDICINE COMMUNICATIONS, 22(4), 367–374.
Vancouver
1.
MONSIEURS M, Thierens H, Vral A, BRANS B, De Ridder L, Dierckx R. Patient dosimetry after I-131-MIBG therapy for neuroblastoma and carcinoid tumours. NUCLEAR MEDICINE COMMUNICATIONS. 2001;22(4):367–74.
MLA
MONSIEURS, MA, Hubert Thierens, Anne Vral, et al. “Patient Dosimetry After I-131-MIBG Therapy for Neuroblastoma and Carcinoid Tumours.” NUCLEAR MEDICINE COMMUNICATIONS 22.4 (2001): 367–374. Print.
@article{168582,
  author       = {MONSIEURS, MA and Thierens, Hubert and Vral, Anne and BRANS, B and De Ridder, Leo and Dierckx, Rudi},
  issn         = {0143-3636},
  journal      = {NUCLEAR MEDICINE COMMUNICATIONS},
  language     = {eng},
  number       = {4},
  pages        = {367--374},
  title        = {Patient dosimetry after I-131-MIBG therapy for neuroblastoma and carcinoid tumours.},
  volume       = {22},
  year         = {2001},
}

Web of Science
Times cited: